Literature DB >> 6850628

Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil.

P Klubes, I Cerna.   

Abstract

We examined the ability of uridine to increase the therapeutic index of 5-fluorouracil (FUra) against C57BL/6 X DBA/2 F1 mice bearing a Day 1 B16 melanoma or L1210 leukemia. FUra (400, 600, or 800 mg/kg, i.p.) followed in 24 hr by a 5-day s.c. infusion with uridine (5 g/kg/day, s.c.) was compared with the maximum tolerated dose of FUra (200 mg/kg, i.p.) plus a 5-day infusion with 0.9% NaCl solution. High-dose FUra plus delayed infusion with uridine was more effective than FUra (200 mg/kg) in inhibiting the growth of the B16 melanoma. High-dose FUra plus uridine rescue was, however, no more effective than FUra (200 mg/kg) in increasing the survival times of mice bearing the L1210 leukemia. To see if uridine rescue from FUra toxicity correlated with effects against a sensitive normal tissue, bone marrow nucleated cellularity of normal, non-tumor-bearing mice was monitored after drug treatment. In mice treated with FUra (200 mg/kg) followed in 24 hr by a 5-day infusion with either uridine (5 g/kg/day) or 0.9% NaCl solution, there was not as great a decrease in cellularity at the nadir with uridine, and, in addition, uridine accelerated recovery as compared to 0.9% NaCl solution. Furthermore, uridine (5 g/kg/day), but not thymidine (dThd) (5 g/kg/day) or 2'-deoxyuridine (dUrd) (5 g/kg/day), had a sparing effect on the depression in bone marrow nucleated cellularity seen at the nadir on Day 4 after Fura (200 mg/kg). The specificity of uridine to rescue mice from the lethal toxicity of the related fluorinated pyrimidines, 5-fluorouridine and 5-fluoro-2'-deoxyuridine, was also examined. Mice were treated with 5-fluorouridine (250 mg/kg, i.p.) followed in 24 hr by a 5-day infusion with uridine (1, 5, or 10 g/kg/day), dThd (1, 5, or 10 g/kg/day), or dUrd (1 or 5 g/kg/day). Uridine (1, 5, or 10 g/kg/day) rescued mice from the lethal toxicity of 5-fluorouridine, whereas dThd or dUrd was ineffective. Similarly, a 5-day infusion with uridine, but not dThd or dUrd, rescued mice from the lethal toxicity of 5-fluoro-2'-deoxyuridine (1800 mg/kg, i.p.).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6850628

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine.

Authors:  D S Martin; R L Stolfi; R C Sawyer
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Comparison of the bioavailability of uridine in mice after either oral or parenteral administration.

Authors:  P Klubes; D B Geffen; R L Cysyk
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Effects of 5-benzylacyclouridine, an inhibitor of uridine phosphorylase, on the pharmacokinetics of uridine in rhesus monkeys: implications for chemotherapy.

Authors:  J P Sommadossi; E M Cretton; L B Kidd; H M McClure; D C Anderson; M H el Kouni
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  Biochemical consequences of 5-fluorouracil gastrointestinal toxicity in rats; effect of high-dose uridine.

Authors:  J Kralovanszky; N Prajda; S Kerpel-Fronius; T Bagrij; E Kiss; G J Peters
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Schedule-dependency of in vivo modulation of 5-fluorouracil by leucovorin and uridine in murine colon carcinoma.

Authors:  J C Nadal; C J van Groeningen; H M Pinedo; G J Peters
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850

6.  Modulation of the effects of fluoropyrimidines on toxicity and tumor inhibition in rodents by uridine and thymidine.

Authors:  H R Hartmann; W Bollag
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

7.  In vitro biochemical and in vivo biological studies of the uridine 'rescue' of 5-fluorouracil.

Authors:  G J Peters; J van Dijk; E Laurensse; C J van Groeningen; J Lankelma; A Leyva; J C Nadal; H M Pinedo
Journal:  Br J Cancer       Date:  1988-03       Impact factor: 7.640

8.  Liquid Chromatography Mass Spectrometry-Based Metabolite Pathway Analyses of Myeloma and Non-Hodgkin's Lymphoma Patients.

Authors:  Carl Angelo D Medriano; Jinhyuk Na; Kyung-Min Lim; Jin-Ho Chung; Youngja H Park
Journal:  Cell J       Date:  2017-05-17       Impact factor: 2.479

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.